Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health: Mental Health

nView Health Delivers Advanced Behavioral Health Screening Functionality

Leave a comment


nView digital assessment solutions allow doctors to screen and interview patients remotely.


ATLANTA (PRWEB)

nView Health, a provider of innovative software solutions that help identify, diagnose, and monitor patients with behavioral health conditions, announced today the general availability of its latest release, which includes capabilities that allow healthcare providers to automatically track and monitor patient progress over time and gives healthcare providers greater flexibility.

This new version, v1.9.1, closely follows another major release that the company issued in February, which included the addition of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) interview and the Children Yale-Brown Obsessive Compulsive Scale (CY-BOCS). These give the clinicians the ability to add notes and information within each interview for greater clarity and enhanced security to meet HITRUST password standards.

“The demand for access to mental health professionals has never been greater than today. And at nView, we’re deploying new solutions that help healthcare providers remotely diagnose and monitor patients more accurately and efficiently so they can help more patients,” said Jim Szyperski, CEO of nView Health. “nView digital assessment solutions allows doctors to screen and interview their patients remotely in advance of their consultation. And since our solutions screen for virtually all major psychiatric disorders in one solution, doctors have a more complete and accurate picture of patients right from the start.”

New Features Added

  • nView Monitors: Ideal for health systems and behavioral health practices that are operating within value-based care networks. The new nView Monitors help capture patient-reported data at physician-defined intervals automatically so they can proactively monitor and report on outcomes. The Monitors include, but are not limited to, Major Depressive Disorder, Social Anxiety Disorder, Substance Abuse Disorder, PTSD, OCD, ADHD (Adult), and several eating disorders.

  • Customizable Landing Pages: Healthcare providers can easily customize web pages within the survey tools that clinicians and patients see before and after completing online assessments. This allows providers to include their own branding and messaging to inform and guide patients throughout the process.

  • Administrator Flexibility: The pediatric version of the online structured diagnostic interview, the MINI-KID, can now be edited within 24 hours of completion, as young patients sometimes rethink their answers, allowing physicians to make the changes. In addition, a new Report History capability documents all versions of the interview, so any changes are auditable.

  • Among several other features, the company is also deploying new online video-based user training guides to support administrators and users of the system.

A Proven Track Record

nView Health has spent years building and deploying digital mental health assessment solutions, including its flagship product, the digital Mini-International Neuropsychiatric Interview (M.I.N.I.), that is based on the world’s most widely validated assessment, and cited in more than 17,000 clinical studies and trials. With responsive algorithms that drive the presentation of only the most relevant questions based on patient’s answers, the digital M.I.N.I. takes an average of less than 20 minutes to complete, compared to the 45-60 minutes required by many other structured psychiatric interviews. This short, structured diagnostic interview evaluates common DSM-5 and ICD-10 psychiatric disorders.

About nView

nView offers behavioral health technology that enables healthcare professionals, researchers, and educators to rapidly deliver the right diagnosis, resulting in the right treatment at the right time. Its signature product, the digital M.I.N.I., allows providers to deliver validated diagnostic behavioral health screens, interviews, outcome tracking, and billable services to patients in a simple, easy-to-use platform. To learn more, please visit nview.com or follow nView on LinkedIn or Twitter.

Share article on social media or email:

Health

New Statistics on How COVID-19 is Affecting Travel Nursing

Leave a comment


I’ve never seen anything like this in almost 15 years of being in this industry.


LANCASTER, Pa. (PRWEB)

The travel nurse industry is stepping up to fill the desperate need for nurses during the COVID-19 crisis. This week new data from TravelNurseSource.com reveals just how much travel nurse specialties are being affected by COVID-19.

TravelNurseSource.com, the leading online career platform for travel nurses and travel nurse agencies, is releasing proprietary data on the travel nursing job demand amid the COVID-19 crisis. The data reveals the transformation in travel nurse job demands from March 2020 compared to February 2020.

The findings showed that demand for certain travel nursing specialties increased drastically from February 2020 to March 2020 when compared to normal industry trends. For example:


  • ICU/Critical Care – increased by 59%

  • RNFA – increased by 64%

  • ER/Trauma – increased by 62%

  • Med/Surg – increased by 14%

Meanwhile, the following specialties saw a decrease in job demand during the same time frame:

  • Pain Management – decreased by 49%

  • PICU – decreased by 29%

  • Pediatrics – decreased by 28%

  • OR – decreased by 16%

While many healthcare workers expected some of these specialties to increase or decrease during a virus outbreak such as COVID-19, the data is still eye-opening. It calls attention to the areas and specialties that are most needed during a situation such as this.

The data also exposed the most hard-hit areas and locations where travel nurses are needed the most. For example, the following locations had the largest increase in demand from February 2020 to March 2020 when compared to normal industry trends.

  • Washington – increased by 93%

  • Rhode Island – increased by 87%

  • Massachusetts – increased by 79%

  • South Dakota – increased by 76%

  • New Jersey – increased by 63%

  • New York – increased by 61%

In addition to the rise and fall of demand in certain nurse specialties, TravelNurseSource.com also found that pay-rates for nurses willing to travel to designated crisis areas increased by 76%. So, not only is the demand high for many travel nursing specialties, but so is the pay.

As expected, TravelNurseSource.com, along with other niche job boards, has pivoted its marketing efforts towards certain specialties and locations and away from others in order to meet the demand of the industry. This includes directing applicants to crisis jobs right away, providing up-to-date information on changes to the industry, and tracking how these trends will fluctuate as the virus impact starts to level off across the country.

“I’ve never seen anything like this in almost 15 years of being in this industry,” said Oliver Feakins, President and owner of TravelNurseSource.com’s parent company, TrackFive.

TravelNurseSource.com is a travel nursing job board owned by TrackFive. TrackFive is a privately held technology company that was founded in 2007 in Lancaster, Pa. As a corporate holding company, TrackFive owns a network of industry-specific websites, from trucking to healthcare, that present unique marketing and promotional opportunities for clients. The websites include TravelNurseSource.com, AlliedTravelCareers.com, LocumJobsOnline.com, and AllTruckJobs.com. The brands are designed to help clients find a steady stream of highly qualified referrals. From referral generation to job boards and online advertising, TrackFive websites feature outstanding resources designed to complement and enhance existing marketing initiatives for its clients across the nation. Learn more at https://trackfive.com/.

Share article on social media or email:

Industry: Healthcare

NeoTract Designates Dr. Jay Page as UroLift® Center of Excellence

Leave a comment


News Image

“This designation recognizes Dr. Jay Page as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson


PLEASANTON, Calif. (PRWEB)

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Jay Page, M.D., Arizona Institute of Urology in Tucson, AZ, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Page has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Jay Page as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

Health

Pharmaceutical Market Squeezed by Supply Chain Disruption and Lower Research Activity

Leave a comment


Strategic Directions International logo


ARLINGTON, Va. (PRWEB)

SDi, part of Science and Medicine Group, is the leading research and advisory firm covering the analytical instrumentation market. In their latest report, Pharmaceutical Market Opportunity 2020, SDi evaluates the global analytical instrument market for the pharmaceutical and biotechnology industry amid the COVID-19 crisis.

SDi predicts pressure on pharmaceutical companies stemming from disruptions in the supply chain of active pharmaceutical ingredients in addition to a decrease in new drug development from reduced lab research activity. However, investment into COVID-19 research will drive growth during this period.

With the virus originating in China, closures among major producers of active pharmaceutical inputs (APIs) squeezed the supply of inputs by between 10-20%. India also suspended the export of key ingredients causing shortages around the world and especially in the United States.

The United States responded with legislation designed to encourage the production of domestic APIs. The Securing America’s Medicine Cabinet Act (SAM-C) expands the FDA’s Emerging Technology Program and authorizes $100 million to build centers of excellence for advanced pharmaceutical manufacturing to help therapeutic development and manufacturing in the US.

The combination of pressure from COVID-19 will affect the market on both ends. Research will be limited from the closure of labs. Bioinformatics, the leading research and advisory firm covering the life sciences market, recently conducted a survey showing that 12% of global research labs are fully operational. Half of all research labs are shut down while the rest are running at a reduced capacity. This survey also includes pharma and biotech labs, which are at the forefront of R&D for this industry. Therefore, many drug discovery processes are also hindered by the global outbreak.

However, all is not lost. The race to find a cure for COVID-19 through the development of a reliable vaccine has begun. Currently, there are 155 medicines and 70 vaccines for the novel coronavirus in the development pipeline. Genetic vaccine platforms using DNA/RNA manipulation seems to be leading the race. This type of vaccine can potentially be developed and produced more quickly than traditional vaccines. As SDi’s report shows, all of this would not be possible without analytical instruments at the heart of each discovery.

SDi’s newly published report, titled The 2020 Pharmaceutical Market Opportunity, evaluates the global analytical instrument market for the pharmaceutical and biotechnology industry. The report covers 74 different analytical techniques, categorized into 10 technological segments. The goal of this report is to provide a strategic perspective on the current situation and projected potential for analytical techniques used in pharmaceutical and biotech industries. Amid the coronavirus chaos, the pharma/bio sector is a unique market, as it is both hindered and stimulated by this pandemic. This report will examine the future direction of laboratory sales to pharma/bio, and how they being affected by this sudden macroeconomic impact, at least in the short term.

The 2020 Pharmaceutical Market Opportunity report can be found at https://strategic-directions.com/product/the-2020-pharmaceutical-market-opportunity-report/.

About Strategic Directions International

Strategic Directions International (SDi), part of Science and Medicine Group, is the leading business intelligence firm in the highly specialized field of analytical and life science instruments. Its client list includes virtually every major analytical instrumentation company in the United States, Europe, and Japan. Founded in 1981, the Los Angeles-based company has published hundreds of market reports and provided proprietary consulting services for a multitude of clients.

Share article on social media or email:

Industry: Healthcare

Leading Angel Investor Group Hosting 10th HyperAccelerator Program, Targeting Impact Companies

Leave a comment


While the program will be open to a variety of impact ventures, RVC is encouraging entrepreneurs to apply that are developing technologies that can aid in the COVID-19 response effort or that could be viable detection or mitigation solutions for future pandemics.


DENVER (PRWEB)

What if venture capitalists had identified and invested in novel solutions to pandemics ten years ago? We would all be in a better place.

Rockies Venture Club (RVC), the largest angel investor group in Colorado, is hosting their next Impact HyperAccelerator program on June 22nd through June 29th, 2020. The program is designed to help seed-stage startups prepare to raise money from venture capital and angel investors. The accelerator consists of a series of intense sessions, following the “Learn – Do – Present and Defend” model in which companies work closely with mentors to develop defensible valuations, venture capital term sheets, capital stack strategies, financial proformas, hypergrowth marketing, due diligence readiness and pitch training. The program’s capstone is a virtual investor Demo Day with 100+ accredited investors and startup supporters in attendance. This Demo Day is followed by RVC’s syndication investment process for those companies that garnered the greatest interest from RVC’s angel investor network.

This iteration of the HyperAccelerator centers on for-profit social or environmental impact companies in sectors such as healthcare, cleantech, education tech, agriculture tech, climate, water, energy and materials science. This summer’s accelerator will be the 10th cohort of the program created by RVC. This HyperAccelerator, however, will be the first to be offered in a completely virtual environment using a variety of collaborative technologies to engage 10 companies and over 50 investor mentors set to take part.

While the program will be open to a variety of impact ventures, RVC is encouraging entrepreneurs to apply that are developing technologies that can aid in the COVID-19 response effort or that could be viable detection or mitigation solutions for future pandemics. Peter Adams, RVC’s Executive Director and Managing Partner at the new Pandemic Impact Fund, added, “It’s clear that the world is at least a decade behind in pandemic preparedness. We have an opportunity now to identify, support, and fund companies that are innovating in pandemic preparation and response with solutions bridging public and private entities.”

While many venture capital funds and private investors are choosing to constrain capital during this period of economic uncertainty, RVC and its network are opting to support early-stage entrepreneurs and startups by remaining active and deploying investments.

Founders or prospective mentors interested in applying to participate or learning more about the RVC Impact HyperAccelerator can visit http://www.hyperaccelerator.org. The deadline for applications is May 15th, 2020.

About the Rockies Venture Club: Rockies Venture Club is the longest-running and one of the largest Angel Groups in the U.S.A., founded in 1985, whose mission is to advance economic development by actively connecting the most promising entrepreneurial companies with Angel investors, venture capitalists, and other community members. Every year Rockies Venture Club offers over 140 educational programs, mastermind groups, Angel forums, and two major conferences for both investors and entrepreneurs.

Share article on social media or email:

Health

“In Depth” With Laurence Fishburne Covers Innovative Products For Those Suffering From Arthritis and Joint Pain

Leave a comment


News Image

In the U.S., over 54 million people have arthritis, and more than 1 in 4 adults experience severe joint pain.


MIAMI (PRWEB)

Recipient of numerous awards for his noteworthy performances throughout the years, actor Laurence Fishburne is the host of the show “In Depth”. “In Depth” is an informational program that highlights a wide array of topics that affect viewing audiences across the country. Airing soon is an episode taking a turn into the medical field. Experts will discuss innovative products for treating joint and arthritic pain.

In the U.S., over 54 million people have arthritis, and more than 1 in 4 adults experience severe joint pain. For years medications have been a primary treatment for arthritis and joint pain, but now there are more options available.

Arthritis gloves are an alternative for those who have inflammation in their fingers and wrists from rheumatoid arthritis. Heat or cold packs are other options for different forms of arthritis. Heat increases blood flow to areas of discomfort, while cold constricts blood vessels to decrease inflammation. Another alternative for arthritis and joint pain are topical NSAIDs. These anti-inflammatory drugs work directly to reduce the swelling that causes joint pain.

Arthritic and joint pain does not have to be debilitating. Gloves, hot and cold packs, and topical drugs are just some of the treatments available. Experts will further explore Arthritic and joint pain treatment options in the new episode of “In Depth.”

“In Depth” with Laurence Fishburne is cautiously reviewed broadcast to a broader viewing audience. The educational program has accepted multiple awards for its efforts.

Share article on social media or email:

Industry: Healthcare

PolyU Study Shows One in Eight Not Wearing Face Masks Properly Almost 80% of People Reusing Them

Leave a comment



HONG KONG (PRWEB)

In February, the research team conducted an observational study of 10,211 people in different areas of Hong Kong, recording how people wear their masks. The study found that most people wore face masks when going out (95%) of whom 84% wore disposable surgical masks. However, more than one-eighth (13%) wore their surgical masks incorrectly; major mistakes include: wearing a mask inside-out or upside-down (36%) and wearing it too low exposing their nostrils and/or mouth (43%).

The team has also been conducting an online survey since mid-March to collect local citizens’ views and attitudes on wearing face marks. Among the 2,859 responses collected so far, most respondents (94%) agreed that wearing a face mask could prevent infection and reduce the risk of viral transmission in the community. However, a significant number of respondents said that they would reuse face masks (76%), with people in the 46-65 and >65 age groups showing a higher percentage of reuse.

Despite heightened awareness of the need for prevention of viral spread, many fail to wear their masks properly

According to Dr Shara Lee, Associate Professor of the Department of Health Technology and Informatics who led the study, the majority of the public have been on high alert and have taken effective preventive measures since the outbreak of COVID-19, and wearing face masks is seen as one of the key measures in the fight against the disease. “Our studies found that people have a high awareness of COVID-19 and agree that wearing face masks is an effective way to prevent viral transmission and community outbreak.” said Dr Lee.

Many of them put this into practice by consistently wearing a face mask. However, despite months of public health education, one in eight have not mastered the correct way to wear a surgical mask. Surprisingly, nearly 80% of the respondents said they would reuse them. This shows that reuse of disposable face masks is widely accepted by the public, probably due to reasons such as an inadequate supply, poor awareness a mask’s disposable nature, financial reasons or receiving incorrect information. These factors potentially increase the risk of transmission and infection, and project a false sense of security when people wear a mask in the belief that they are now protected. The situation is worrying.

Page 1

The research team identified some common mistakes when using face masks:

  • Wearing the mask inside-out or upside-down

  • Positioning it too low on the face, exposing the nostrils and/or mouth

  • Touching the outer layer of the mask during use or disposal

  • Pulling down the mask when eating or smoking, or hanging the mask around the neck/other part of the body

Keep up the anti-pandemic effort Do your bit by wearing a face mask correctly

The fight against the COVID-19 outbreak requires perseverance and the cooperation of every member of the public. The research team advises that the public should “do the right thing” by adhering to the proper practices of wearing face masks at all times and keep up the hard-earned effort in containing the community outbreak.

The team also recommends solutions to improve protection from infection due to improper use of face masks, including:


  • Experts formulating comprehensible guidelines for safe handling and storage of face masks for reuse, to minimize the risk of both virus spread and self-contamination

  • Publicity and education on the potential risks of incorrect use of face masks

  • Printing a symbol on the outer layer of the face mask to indicate correct orientation

  • Inclusion of information made available by face mask manufacturers, e.g. a clear visual guide or QR code printed on the box for easier access.

Share article on social media or email:

Health

Brenntag Canada and Fuji Chemical Industries Announce Exclusive Distribution Agreement

Leave a comment


News Image


READING, Pa. (PRWEB)

Fuji’s premium line of excipients is produced using their spray drying capabilities and includes Neusilin®, Fujicalin®, F-MELT®, and FujiSil™.


  • Neusilin® – is Magnesium Aluminometasilicate USP/EP/JP. It improves powder flowability, is an excellent adsorbent for oily actives, is an anticaking agent, and acts as a stabilizer for deliquescent drugs.

  • Fujicalin® – is a unique form of Dibasic Calcium Phosphate Anhydrous (DCPA). It provides flowability, rapid disintegration, high direct compressibility, high oil adsorption capability, is non-abrasive, and can improve survivability of probiotics during tableting.

  • F-MELT® – ready-to-use excipient base for ODTs. It provides an easy way to produce fast melt tablets on conventional tableting equipment that disintegrate within 30 seconds. It is directly compressible, extremely flowable, and produces tablets with excellent mouth feel.

  • FujiSil™ – is a unique form of Silicon Dioxide USP/NF. It is a versatile excipient that has superior adsorption properties and can turn oily actives into a free-flowing powder, improve tabletability, be used as a carrier for solid dispersions, and aids in moisture protection.

“The addition of Fuji’s premium line of excipients is a testament to our dedication in strengthening our overall offering to the Canadian Pharmaceutical and Nutraceutical markets,” states Jim Sally, Vice President, Brenntag Canada. “The addition of this product line to our current portfolio and dedicated technical staff gives Brenntag a solid and exciting value proposition for our customers.”

Since 1946, Fuji has been producing excipients at their manufacturing site in Toyama, Japan. These excipients can be used in pharmaceutical, dietary supplement, nutraceutical, personal care, and CBD/cannabis applications.

“We are pleased to add Fuji Chemical’s specialty excipients to the Pharmaceutical and ingredients portfolio at Brenntag. This exclusive agreement will benefit our customer base by providing a local touch to support their development,” said Anne-Marie Gaudet, Pharmaceutical Industry Manager, Brenntag Canada.

About Brenntag:

Brenntag is the global market leader in chemical and ingredients distribution. We connect our suppliers and customers in value-adding partnerships. Our almost 17,500 employees provide tailor-made application, marketing and supply chain solutions. Technical and formulation support, market, industry and regulatory expertise as well as advanced digital tools are just some examples of our services that are aiming to create an excellent customer experience. Our full-line portfolio comprises specialty and industrial chemicals and ingredients of a world-class supplier base. Building on its long-standing experience, unmatched global reach and local excellence, Brenntag works closely alongside its partners to make their business more successful. We are committed to contribute towards greater sustainability in our own business and the industries we serve, and to achieve sustainable profitable growth. Headquartered in Essen (Germany) and with regional headquarters in Philadelphia, Houston and Singapore, Brenntag operates a unique global network with more than 640 locations in 77 countries. The company generated sales of EUR 12.8 billion (USD 14.4 billion) in 2019. Brenntag shares are traded at the Frankfurt Stock Exchange (BNR).

For more information on Brenntag North America, please visit http://www.brenntagnorthamerica.com.

About Fuji Chemical Industries co., LTD, USA, Inc .:

Fuji Chemical Industries Co., Ltd. is engaged in the production and sale of pharmaceutical products/synthesis, the manufacture of pharmaceutical and bulk pharmaceutical products, and the production and sale of food additives. It offers contract manufacturing services that include API manufacturing; functional APIs, such as drug intermediates; and drug products manufacturing. The company also provides excipients and drug delivery systems.

For more information on Fuji Chemical Industries USA, Inc, please visit http://www.fujichemicalusa.com.

Credits: The Brenntag and ConnectingChemistry logos are registered trademarks of Brenntag AG or its subsidiaries. Neusilin®, Fujicalin®, F-MELT® and FujiSil™ are registered trademarks of Fuji Chemical Industries USA, Inc. Any other trademarks are the property of their respective owners.

Share article on social media or email:

Industry: Healthcare

Veinlite PEDI2 – A New Age in Pediatric IV Access

Leave a comment


The New Veinlite PEDI2

Veinlite PEDI2 offers an 18mm opening (29% larger than PEDI), plus light color selection and brightness control.

The PEDI2 makes intravenous access in children less invasive than ever before.


SUGAR LAND, Texas (PRWEB)

TransLite LLC, maker of the bestselling Veinlite® brand of vein access devices for healthcare providers, today announced the launch of the all-new PEDI2 for use in pediatric patients.

The Perfect Solution of Reducing Needle Sticks in Children

The PEDI2 was specifically designed to prevent children from suffering multiple sticks during venipuncture procedures. Without the PEDI2, the current Standard of Care is 72.2% first-stick success rate, with some children subjected to several failed attempts. That’s where PEDI2 comes in, representing the cutting edge in pediatric vein access and offering the optimal combination of price, performance, and simplicity.

“No child should have to suffer multiple sticks during medical treatment,” said Nizar Mullani, TransLite LLC’s founder. “The PEDI2 makes intravenous access and blood draws in children much easier, and less invasive than ever before. Every healthcare worker seeks to deliver better patient care, and PEDI2 is the only device that can deliver one-stick success.”

Focus on Continued Innovation

The award-winning Veinlite product line is recognized the world over for its portable, lightweight, and easy to use vein access devices. The PEDI2 takes that legacy of innovation even further. This new model is the result of over two years of design, engineering and prototype development – all focused on delivering the best vein access device for children of all ages (0-17 years). The original Veinlite PEDI was proven to increase first-stick success rate to 93%, making it the most accurate device for pediatrics. TransLite’s goal was to make it even better. PEDI2 outperforms the original PEDI in every way, adding new features like 3-way brightness control, 29% larger opening, and longer battery life. 

Key Features:

  • Clinically proven to improve vein access success rates over Standard of Care

  • 18mm opening reveals larger area for vein imaging

  • Locks vein in place during needle sticks – prevents vein rolling

  • Color selection: orange, red, orange + red

  • 3 levels of brightness control

Helping You Achieve Infection Control Measures

The PEDI2 also meets INS Guidelines for infection control, a critical consideration when providing healthcare treatment to any patient, especially children. Low-cost PEDI2 disposable plastic covers are easy to use and effective in preventing patient-to-provider and patient-to-patient contamination.

Veinlite PEDI2 is available immediately. US customers can purchase direct from the company’s website, veinlite.com (includes an exclusive five-year extended warranty). For customers in other countries and territories, please see Veinlite’s Authorized International Distributors.

To learn more about the new Veinlite PEDI2® – or TransLite’s complete line of IV access and Sclerotherapy vein finders – visit https://www.veinlite.com. For more information or to schedule an interview, contact Katie Schertler at (281) 240-3111 or info(at)veinlite(dot)com

Share article on social media or email:

Health

New Webinar Series From Lachman Consultants Provides Valuable Information To The Pharmaceutical Industry

Leave a comment


“These webinars enable Lachman’s team of SMEs and industry experts to bring their unmatched knowledge and expertise to life science organizations at a time when they can benefit from them the most.” – Ricki A. Chase, M.S. Executive Director in the Compliance Practice, Lachman Consultants


WESTBURY, N.Y. (PRWEB)

Ever a responsive and supportive partner to its clients, these webinars are Lachman Consultants latest effort in providing timely and critical information to life science organizations as they navigate the ever-changing economic and business environment, further complicated by social distancing and health safety concerns.

“Providing the most up-to-date actionable guidance and information has been a keystone of our long-standing client relationships,” commented Ricki A. Chase, M.S. Executive Director in the Compliance Practice, Lachman Consultants, stated. “These webinars enable Lachman’s team of SMEs and industry experts to bring their unmatched knowledge and expertise to life science organizations at a time when they can benefit from them the most.”

The first two webinars in the series focus on FDA inspections. The initial installment, entitled “Preparing for and Handling an FDA Inspection,” will be hosted by Ricki Chase, former FDA Director of the Investigations Branch in the Chicago District. Ricki will be joined by Linda Evans O’Connor, Vice President, Chief of Staff, Lachman Consultants.

The hour-long “Preparing for and Handling an FDA Inspection” webinar will help organizations comprehensively plan for and navigate the various stages, details and technicalities before, during, and after an FDA inspection. Among the topics discussed will be an overview of the FDA and GMPs, FDA Inspections and Enforcement Actions, and the various steps in organizing for an FDA Inspection.

The second Lachman Consultants’ webinar in the series, “How to Respond to Inspectional Observations” will be held on Thursday, May 21st at 2:00 pm EDT and will also be hosted by Ricki Chase, former FDA Director of the Investigations Branch in the Chicago District. Joining her will be Linda Evans O’Connor, Vice President, Chief of Staff, Lachman Consultants. Topics for this webinar will include responding to 483s, summarizing a commitment to sustainable compliance, providing corrective actions, and establishing a practical timeline.

For more information about Lachman Consultants’ webinars, visit: https://www.lachmanconsultants.com/lachman-learning/.

To sign up for “Preparing for and Handling an FDA Inspection,” please go to: https://www.lachmanconsultants.com/lachman-learning/webinar-preparing-for-an-fda-inspection/

To sign up for “How to Respond to Inspectional Observations,” please go to:

https://www.lachmanconsultants.com/lachman-learning/webinar-how-to-respond-to-inspectional-observations/.

2020 © Lachman Consultants

ABOUT LACHMAN CONSULTANTS

Founded in 1978, Lachman Consultants maintains three practice groups: Compliance, Regulatory Affairs, and Science and Technology. Each practice offers industry-leading experience and expertise in its area of focus. Lachman Consultants serves emerging-to-enterprise organizations on a worldwide basis in the Pharmaceutical, Biotechnology, Biologics, Device, and Related Life Science Industries. Lachman Consultants deliver highly effective and proven solutions that include FDA-Related Services, Audits, Quality Assurance & Controls, Scientific and Technical Assistance, Systems Evaluation, and Training, which have been shown to consistently exceed client requirements and expectations.

For additional press information, please contact:

Ilena Della Ventura

Delia Associates

T. 908-534-9044

Share article on social media or email: